Mr. David Pidduck reports

MEDIPHARM LABS TO ENTER NEW MARKET WITH COSTA RICA SUPPLY AGREEMENT

Medipharm Labs Corp. has signed a definitive supply agreement with Remidose Aerosols Inc. for the shipment of GMP-(good manufacturing practice)-certified medicinal cannabis products to Costa Rica.

"Medipharm Labs' proven ability to navigate complex regulatory environments enables us to deliver GMP-certified cannabinoid products to highly regulated markets worldwide," says David Pidduck, chief executive officer of Medipharm Labs. "This agreement strengthens our commitment to supporting medical patients in Costa Rica and advancing international access to quality cannabis solutions."

Costa Rica's medical cannabis market officially opened to regulated sales in June, 2025, and is projected to exceed $35-million (U.S.) annually, driven by strong patient demand and a comprehensive regulatory framework focused on product safety and GMP compliance.

Under the agreement, Medipharm Labs will supply a range of GMP-certified cannabis products including oils, tinctures, metered dose inhalers and dried flower to Remidose's affiliated entity, Remidose LATAM SRL. Remidose LATAM has already advanced its regulatory process, and shipment will begin once the remaining requirements are completed.

"Remidose LATAM is proud to be fully licensed and authorized by Costa Rican health authorities to import medicinal cannabis products. Partnering with Medipharm Labs allows us to offer patients access to some of the highest-quality, GMP-certified cannabis products available globally. Medipharm's standards, reliability and proven ability to deliver in regulated markets make them the ideal partner for our mission to improve patient care in Costa Rica," commented Michael Mayne, president of Remidose.

About Remidose and Remidose LATAM

Remidose Aerosols specializes in innovative cannabis delivery systems including metered-dose inhalers, that are now made in partnership with Medipharm Labs and advanced topical formulations. Remidose LATAM focuses on providing high-quality medicinal cannabis products in compliance with local regulations. It is co-founded by Remidose and Costa Rican cannabinoid entrepreneur, Ludwig Muller.

About Medipharm Labs Corp.

Founded in 2015, Medipharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a good manufacturing practices certified facility with ISO standard-built clean rooms. Medipharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. Medipharm Labs develops, formulates, processes, packages, and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.

We seek Safe Harbor.